Can antiviral therapy lower risk of liver cancer?

WrittenBy

Written By: Editorial Team | Published : June 25, 2014 7:14 PM IST

liverAntiviral therapy can reduce the risk of liver cancer in patients with chronic hepatitis B infection, researchers have found. The licensed oral antiviral agent nucleos(t)ide (NUC) resulted in a reduced long term risk for liver cancer chronic hepatitis B patients, the findings showed. 'Our findings suggest that NUC use reduces the risk of liver cancer in chronic hepatitis B patients, particularly in younger patients with minimal liver damage,' said Chun-Ying Wu from National Yang-Ming University in Taiwan. (Read: Keep your liver healthy with these 5 natural remedies (Gallery))

This study analysed the risk of hepatocellular carcinoma, the most common form of liver cancer, in patients treated with several different agents. The NUC-treated cohort had a significantly lower seven-year incidence of liver cancer compared with a control group. Liver cancer among hepatitis B patients causes approximately 745,000 deaths worldwide each year. The findings appeared in the journal Gastroenterology. (Read: 9 tips to prevent liver disease (Gallery))

What is liver cancer?

It is a condition that can be caused by many factors including viral infections (hepatitis B and C), chronic alcoholism, certain food contaminants, genetic factors, cirrhosis of the liver. It is when the cells within the liver multiply unnaturally leading to formation of a mass or scar tissue. Scar tissue is a type of tissue that forms over a damaged area of the liver. It is the body's way of healing. Unfortunately this tissue leads to the improper functioning of the liver and can lead to cancer.

You may also like to read:

With inputs from IANS

For more articles on cancer, visit our cancer section. Follow us on Facebook and Twitter for all the latest updates! For daily free health tips, sign up for our newsletter. And to join discussions on health topics of your choice, visit our forum.